We studied the efficacy and safety of levofloxacin (LVFX) at 200 mg b.i.d. for 7 days, and the correlation between efficacy and the AUC/MIC ratio in patients with suspected pneumococcal pneumonia. Subjects were suspected of having mild to moderate pneumococcal pneumonia because pneumococcal antigen was detected in the urine or Gram staining of sputum was positive before the start of treatment. We measured blood LVFX twice in each patient and used the Bayesian method with population parameters to calculate AUC. Of the 71 subjects enrolled, 57 were analyzed for clinical efficacy, and efficacy was 93.0% (53/57). Of these, 46 had pneumococcal pneumonia, diagnosed as positive for Streptococcus pneumoniae by culture or urinary antigen. Efficacy was 93.5% (43/46). Of the 30 in whom S. pneumoniae was isolated and identified, bacterial eradication was 96.7% (29/30). Side effects occurred in 17 of 70 patients, i.e., 15 mild, and LVFX administration was continued. Two had moderate side effects and recovered quickly after LVFX administration was discontinued. The AUC/MIC ratio calculated for 22 patients in whom the MIC of LVFX for S. pneumoniae could be measured was 68.5±31.9 (mean ± S.D.). Of these, only 1 patient was AUC/MIC<25. Considering from above results, it was suggested that 200 mg LVFX administered twice a day could achieve an adequate AUC/MIC ratio and high clinical efficacy in patients with suspected pneumococcal pneumonia.
|Number of pages||11|
|Journal||Japanese Journal of Chemotherapy|
|Publication status||Published - 2004 Dec|
- Streptococcus pneumoniae
ASJC Scopus subject areas
- Pharmacology (medical)